Diversion Control Division, US Department of Justice, Drug Enforcement Administration

ABOUT US > What's New

What's New

May

Michael T. Harris, M.D.; Decision and Order (PDF) (May 18, 2022)

Eric David Thomas, M.D.; Denial of Application (PDF) (May 18, 2022)

Patheon Pharmaceuticals Inc. (PDF) (May 6, 2022)


April

SpecGx LLC (PDF) (April 28, 2022)

Lipomed (PDF) (April 28, 2022)

Royal Emerald Pharmaceuticals Research and Development (PDF) (April 28, 2022)

VHG Labs DBA LGC Standards (PDF) (April 28, 2022)

Sterling Wisconsin, LLC (PDF) (April 28, 2022)

Research Triangle Institute (PDF) (April 28, 2022)

Purisys, LLC (PDF) (April 28, 2022)

SpecGX LLC (PDF) (April 28, 2022)

Brenton D. Wynn, M.D.; Decision and Order (PDF) (April 22, 2022)

Larry S. Everhart, M.D.; Decision and Order (PDF) (April 21, 2022)

Order with Opportunity for Comment: Exempt Chemical Preparations Under the Controlled Substances Act (PDF) (April 19, 2022)

Temporary Placement of Butonitazene, Etodesnitazene, Flunitazene, Metodesnitazene, Metonitazene, N-Pyrrolidino etonitazene, and Protonitazene in Schedule I (PDF) (April 12, 2022)

Proposed Rule: Exempted Prescription Products (PDF) (April 12, 2022)

Final Rule: Requiring Online Submission of Applications for and Renewals of DEA Registration (PDF) (April 11, 2022)

Proposed Rule: Placement of 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC) in Schedule I (PDF) (April 11, 2022)

Jennifer Smith, M.D.; Decision and Order (PDF) (April 11, 2022)

Gilbert Y. Kim, D.D.S.; Decision and Order (PDF) (April 11, 2022)

George Pharmacy, Inc.; Decision and Order (PDF) (April 11, 2022)

Kirk A. Hopkins, M.D.; Decision and Order (PDF) (April 11, 2022)

Kareem Hubbard, M.D.; Decision and Order (PDF) (April 11, 2022)

Noah David, P.A.; Decision and Order (PDF) (April 11, 2022)

Douglas A. Blose, M.D.; Decision and Order (PDF) (April 11, 2022)

David H. Betat, M.D.; Decision and Order (PDF) (April 11, 2022)

Craig S. Rosenblum, M.D.; Decision and Order (PDF) (April 11, 2022)

Christopher King, C.N.P.; Decision and Order (PDF) (April 11, 2022)

Crosby Pharmacy and Wellness; Decision and Order (PDF) (April 11, 2022)

Adam T. Rodman, P.A.; Decision and Order (PDF) (April 11, 2022)

Lezlie McKenzie, N.P.; Decision and Order (PDF) (April 11, 2022)

OakmontScript Limited Partnership; Decision and Order (PDF) (April 11, 2022)

Interim Final Rule: Placement of Daridorexant in Schedule IV (PDF) (April 7, 2022)

Final Rule: Placement of 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA, and FUB-144 in Schedule I (PDF) (April 7, 2022)

Purisys, LLC (PDF) (April 7, 2022)

Meridian Medical Technologies (PDF) (April 6, 2022)


March

Instructions to request exception to 21 CFR 1306.07(b) 3-day rule (EO-DEA248) (PDF) (March 23, 2022)

Johnson Matthey Pharmaceutical Materials, Inc. (PDF) (March 23, 2022)

Sharp Clinical Services, Inc. (PDF) (March 23, 2022)

Siemens Healthcare Diagnostics, Inc. (PDF) (March 23, 2022)

Usona Institute, Inc. (PDF) (March 23, 2022)

Patheon API Manufacturing, Inc. (PDF) (March 23, 2022)

Janssen Pharmaceuticals Inc. (PDF) (March 14, 2022)

ANI Pharmaceuticals, Inc. (PDF) (March 14, 2022)

Meridian Medical Technologies, LLC (PDF) (March 14, 2022)

Sigma Aldrich Co. LLC (PDF) (March 14, 2022)

Perkinelmer, Inc. (PDF) (March 14, 2022)

Agriculture Technology Institute, LLC (PDF) (March 14, 2022)

Peace of Mind Pharmaceuticals LLC (PDF) (March 9, 2022)

60-Day Notice; Extension: Application for Individual Manufacturing Quota for a Basic Class of Controlled Substance and for Ephedrine, Pseudoephedrine, and Phenylpropanolamine; DEA Form 189 (PDF) (March 8, 2022)

60-Day Notice; Extension: Application for Procurement Quota for Controlled Substance and for Ephedrine, Pseudoephedrine, and Phenylpropanolamine; DEA Form 250 (PDF) (March 8, 2022)

60-Day Notice; Extension: Application for Import Quota for Ephedrine, Pseudoephedrine, and Phenylpropanolamine; DEA Form 488 (PDF) (March 8, 2022)

S&B Pharma LLC (PDF) (March 8, 2022)

Tikun Olam Adelanto LLC (PDF) (March 8, 2022)

Caligor Coghlan Pharma Services (PDF) (March 8, 2022)

Siegfried USA, LLC (PDF) (March 8, 2022)

ANI Pharmaceuticals Inc. (PDF) (March 8, 2022)

Sterling Pharma USA, LLC (PDF) (March 2, 2022)

Janssen Pharmaceuticals, Inc. (PDF) (March 2, 2022)

Medi-Physics Inc. dba GE Healthcare (PDF) (March 2, 2022)


February

S&B Pharma LLC (PDF) (February 25, 2022)

Cedarburg Pharmaceuticals (PDF) (February 25, 2022)

Synthcon LLC (PDF) (February 25, 2022)

Lyndra Therapeutics (PDF) (February 25, 2022)

Scottsdale Research Institute (PDF) (February 24, 2022)

Mylan Inc. (PDF) (February 24, 2022)

Myonex Inc. (PDF) (February 24, 2022)

Benuvia Therapeutics Inc. (PDF) (February 24, 2022)

Johnson Matthey Pharmaceutical Materials Inc. (PDF) (February 24, 2022)

Noramco Coventry LLC (PDF) (February 24, 2022)

Scottsdale Research Institute (PDF) (February 24, 2022)

John X. Qian, M.D.; Decision and Order (PDF) (February 11, 2022)

Exempt Chemical Preparations Under the Controlled Substances Act; Correction (PDF) (February 3, 2022)


January 2022

Bradley H. Chesler, M.D.; Decision and Order (PDF) (January 31, 2022)

Austin J. Kosier, M.D.; Decision and Order (PDF) (January 31, 2022)

Michael E. Smith, D.V.M.; Decision and Order (PDF) (January 31, 2022)

Siegfried USA, LLC (PDF) (January 31, 2022)

Navinta, LLC (PDF) (January 31, 2022)

Mylan Pharmaceuticals, Inc. (PDF) (January 31, 2022)

Globyz Pharma, LLC; Correction (PDF) (January 24, 2022)

Order with Opportunity for Comment: Exempt Chemical Preparations Under the Controlled Substances Act (PDF) (January 21, 2022)

Daniel R. Nevarre, M.D.; Decision and Order (PDF) (January 21, 2022)

Stephen E. Owusu, D.P.M.; Decision and Order (PDF) (January 21, 2022)

Alex E. Torres, M.D.; Decision and Order (PDF) (January 21, 2022)

Tel-Pharmacy; Decision and Order (PDF) (January 19, 2022)

AARRIC, Inc. d/b/a at Cost RX; Decision and Order (PDF) (January 19, 2022)

Samson K. Orusa, M.D.; Decision and Order (PDF) (January 19, 2022)

Proposed Rule: Placement of 4-hydroxy-N,N-diisopropyltryptamine, 5-methoxy-alpha-methyltryptamine, 5-methoxy-N-methyl-N-isopropyltryptamine, 5-methoxy-N,N-diethyltryptamine, and N,N-diisopropyltryptamine in Schedule I (PDF) (January 14, 2022)

Organic Standards Solutions International, LLC (PDF) (January 14, 2022)

Curia Missouri Inc. (PDF) (January 11, 2022)

Johnson Matthey, Inc. (PDF) (January 11, 2022)

Nexus Pharmaceuticals, Inc. (PDF) (January 11, 2022)


December 2021

Gulf Med Pharmacy; Decision And Order (PDF) (December 22, 2021)

Organix Inc. (PDF) (December 21, 2021)

Timothy C. Sapp, M.D.; Decision and Order (PDF) (December 20, 2021)

Peter S. Klainer, M.D.; Decision and Order (PDF) (December 20, 2021)

Washington Bryan, M.D.; Decision and Order (PDF) (December 20, 2021)

Medical Pharmacy; Decision and Order (PDF) (December 20, 2021)

Cypress Creek Pharmacy, LLC; Order (PDF) (December 20, 2021)

SpecGX, LLC (PDF) (December 13, 2021)

Noramco, Inc. (PDF) (December 13, 2021)

Noramco Coventry LLC (PDF) (December 9, 2021)

Catalent Pharma Solutions, LLC (PDF) (December 9, 2021)

Fresenius Kabi USA, LLC (PDF) (December 9, 2021)

Tamika Mayo, M.D.; Decision and Order (PDF) (December 8, 2021)

Proposed Amendment: Temporary Placement of Butonitazene, Etodesnitazene, Flunitazene, Metodesnitazene, Metonitazene, N-pyrrolidino etonitazene, and Protonitazene in Schedule I (PDF) (December 7, 2021)

Proposed Rule: Placement of Methoxetamine (MXE) in Schedule I (PDF) (December 7, 2021)

Kinetochem, LLC (PDF) (December 6, 2021)

Johnson Matthey Inc. (PDF) (December 6, 2021)

Fisher Clinical Services, Inc. (PDF) (December 6, 2021)

Final Order: Established Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2022 (PDF) (December 2, 2021)

Emergency Disaster Relief
Search for Year Round Pharmaceutical Disposal Locations.
National Prescription Drug Take Back Day. Turn in your unused or expired medication for safe disposal here.
RX Abuse Online

U.S. DEPARTMENT OF JUSTICE  •  DRUG ENFORCEMENT ADMINISTRATION
Diversion Control Division  •  8701 Morrissette Drive  •  Springfield, VA 22152  •  1-800-882-9539

DOJ Legal Policies and Disclaimers    |    DOJ Privacy Policy    |    FOIA    |    Section 508 Accessibility